Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells
Phase of Trial: Phase I/II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 21 Mar 2017 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 21 Mar 2017 Status changed from not yet recruiting to recruiting.
- 03 Nov 2016 New trial record